Pilot study of chemopreventive effect of pioglitazone for colorectal cancer using aberrant crypt foci as a biomarker

Pilot study of chemopreventive effect of pioglitazone for colorectal cancer using aberrant crypt foci as a biomarker - pioglitazone for colorectal cancer chemoprevention

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001265

Enrollment

Registered

2008-07-24

Start date

2004-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with aberrant crypt foci (ACF)

Interventions

Oral administration of pioglitazone in 15mg daily. No administration of newly drug.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a. Obtaining informed consent b. Positive for ACF

Exclusion criteria

Exclusion criteria: a. Liver cirrhosis or chronic hepatic, chronic renal failure b. Women who are pregnant or with a possibility of pregnancy c. Alcohol dependence or drug dependence d. Drug allergy e. Heart failure f. Those who have started to use different medication for diabetes mellitus from pioglitazone-alone (including insulin) in study period g. The patient that it is already taken pioglitazone h. History of cancer i. Family history of colorectal cancer j. The patient currently taking NSAIDs k. Inadequate to entry to this study

Design outcomes

Primary

Measure	Time frame
Observation of ACF using magnifying endoscopy	—

Countries

Japan

Contacts

Public ContactHirokazu Takahashi

Yokohama City University Graduate School of Medicine Gastroenterology Division

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026